Charmingly eccentric, full of personality, and designed for maximum reader engagement

Vancouver, British Columbia–(Newsfile Corp. – January 28, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it has closed the second and final tranche (the “Second Tranche”) of its non-brokered private placement (the “Offering”) of units of the Company (each, a “Unit”) at a price of $0.30 per Unit. Under the Second Tranche, the Company distributed 1,316,668 Units for gross proceeds of $395,000, bringing the total Offering raise to $934,000.

With the closing of the second and final tranche of its private placement, Optimi Health Corp. continues to make strides in the field of psychedelics pharmaceuticals. The Company’s focus on botanical psilocybin and MDMA sets it apart in the industry, as it works towards providing innovative solutions for mental health treatment.

Optimi’s success in raising a total of $934,000 through its Offering demonstrates investor confidence in the company’s vision and potential for growth. This influx of funds will enable Optimi to further its research and development efforts, potentially leading to groundbreaking advancements in the field of psychedelics.

Impact on Individuals:

As a potential consumer of mental health treatments, Optimi Health Corp.’s advancements in psychedelics pharmaceuticals could offer new, innovative solutions for individuals struggling with various mental health conditions. The company’s focus on botanical psilocybin and MDMA may provide alternatives to traditional treatment methods, giving individuals more options for managing their mental well-being.

Impact on the World:

Optimi Health Corp.’s continued progress in the psychedelics pharmaceutical industry has the potential to impact the world by reshaping the way mental health is approached and treated. By developing new and effective treatments, the company could contribute to a shift in the global perspective on mental health, opening up new possibilities for those in need of support.

Conclusion

Optimi Health Corp.’s successful completion of its private placement marks a significant milestone in the company’s journey towards advancing psychedelics pharmaceuticals. With a focus on botanical psilocybin and MDMA, Optimi is poised to make a meaningful impact on individuals seeking alternative mental health treatments, as well as on the world’s approach to mental well-being.